Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2019 – CLL
ASCO 2019 – CLL
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory CLL
ASCO 2019 – CLL
Phase 2 data show that continuation of Bruton’s tyrosine kinase treatment with acalabrutinib may represent a viable treatment strategy in patients with CLL who have become intolerant to ibrutinib and whose disease has progressed.
Read More ›
Evaluation of the PI3Kδ Inhibitor ME-401 in Patients with Relapsed/Refractory Follicular Lymphoma
ASCO 2019 – CLL
In a phase 1b study, the novel PI3kδ inhibitor ME-401 showed promising response rates with acceptable tolerability when evaluated in a flexible dosing schedule in follicular lymphoma. Additional studies are enrolling patients to further evaluate the clinical potential for this investigative therapy.
Read More ›
Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
ASCO 2019 – CLL
A novel combination of venetoclax, atezolizumab, and obinutuzumab is being studied in patients with Richter transformation of CLL into diffuse large B-cell lymphoma.
Read More ›
Smart Start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead-In Therapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
ASCO 2019 – CLL
The combination of rituximab, lenalidomide, and ibrutinib as lead-in therapy prior to chemotherapy is effective in patients with newly diagnosed diffuse large B-cell lymphoma.
Read More ›
Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL
ASCO 2019 – CLL
In an ongoing phase 1/2 trial, the investigational CAR T therapy lisocabtagene maraleucel induced deep and durable responses, with many patients achieving minimal residual disease (MRD) status to date.
Read More ›
Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE
ASCO 2019 – CLL
Newly reported findings from the iNNOVATE study corroborate earlier reports that ibrutinib has a positive impact on patient-reported outcomes in Waldenström’s macroglobulinemia (WM).
Read More ›
Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM
ASCO 2019 – CLL
In a retrospective analysis, the doublet combination of rituximab plus bendamustine showed better response rates and event-free survival rates than 2 different triplet regimens when given as frontline treatment of Waldenström’s macroglobulinemia (WM).
Read More ›
Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL
ASCO 2019 – CLL
Newly reported findings from the iNNOVATE study corroborate earlier reports that ibrutinib has a positive impact on patient-reported outcomes in Waldenström’s macroglobulinemia.
Read More ›
Page 2 of 2
1
2
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us